The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination
Multiple sclerosis (MS) is a chronic degenerative autoimmune disease of the central nervous system that causes inflammation, demyelinating lesions, and axonal damage and is associated with a high rate of early-onset disability. Disease-modifying therapies are used to mitigate the inflammatory proces...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/4/474 |
| _version_ | 1797445438029168640 |
|---|---|
| author | Eneritz López-Muguruza Natalia Villar-Gómez Jordi A. Matias-Guiu Belen Selma-Calvo Lidia Moreno-Jiménez Francisco Sancho-Bielsa Juan Lopez-Carbonero María Soledad Benito-Martín Silvia García-Flores Natalia Bonel-García Ola Mohamed-Fathy Kamal Denise Ojeda-Hernández Jorge Matías-Guiu Ulises Gómez-Pinedo |
| author_facet | Eneritz López-Muguruza Natalia Villar-Gómez Jordi A. Matias-Guiu Belen Selma-Calvo Lidia Moreno-Jiménez Francisco Sancho-Bielsa Juan Lopez-Carbonero María Soledad Benito-Martín Silvia García-Flores Natalia Bonel-García Ola Mohamed-Fathy Kamal Denise Ojeda-Hernández Jorge Matías-Guiu Ulises Gómez-Pinedo |
| author_sort | Eneritz López-Muguruza |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is a chronic degenerative autoimmune disease of the central nervous system that causes inflammation, demyelinating lesions, and axonal damage and is associated with a high rate of early-onset disability. Disease-modifying therapies are used to mitigate the inflammatory process in MS but do not promote regeneration or remyelination; cell therapy may play an important role in these processes, modulating inflammation and promoting the repopulation of oligodendrocytes, which are responsible for myelin repair. The development of genetic engineering has led to the emergence of stable, biocompatible biomaterials that may promote a favorable environment for exogenous cells. This review summarizes the available evidence about the effects of transplantation of different types of stem cells reported in studies with several animal models of MS and clinical trials in human patients. We also address the advantages of combining cell therapy with biomaterials. |
| first_indexed | 2024-03-09T13:25:49Z |
| format | Article |
| id | doaj.art-efafd131e9fc4b86bdaad29df8d4a742 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T13:25:49Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-efafd131e9fc4b86bdaad29df8d4a7422023-11-30T21:24:41ZengMDPI AGLife2075-17292022-03-0112447410.3390/life12040474The Integration of Cell Therapy and Biomaterials as Treatment Strategies for RemyelinationEneritz López-Muguruza0Natalia Villar-Gómez1Jordi A. Matias-Guiu2Belen Selma-Calvo3Lidia Moreno-Jiménez4Francisco Sancho-Bielsa5Juan Lopez-Carbonero6María Soledad Benito-Martín7Silvia García-Flores8Natalia Bonel-García9Ola Mohamed-Fathy Kamal10Denise Ojeda-Hernández11Jorge Matías-Guiu12Ulises Gómez-Pinedo13Laboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainDepartment of Neurology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainDepartment of Physiology, Ciudad Real School of Medicine, Universidad de Castilla-La Mancha, 13005 Ciudad Real, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainLaboratory of Neurobiology, Institute of Neurosciences, Hospital Clínico San Carlos Health Research Institute, Universidad Complutense de Madrid, 28040 Madrid, SpainMultiple sclerosis (MS) is a chronic degenerative autoimmune disease of the central nervous system that causes inflammation, demyelinating lesions, and axonal damage and is associated with a high rate of early-onset disability. Disease-modifying therapies are used to mitigate the inflammatory process in MS but do not promote regeneration or remyelination; cell therapy may play an important role in these processes, modulating inflammation and promoting the repopulation of oligodendrocytes, which are responsible for myelin repair. The development of genetic engineering has led to the emergence of stable, biocompatible biomaterials that may promote a favorable environment for exogenous cells. This review summarizes the available evidence about the effects of transplantation of different types of stem cells reported in studies with several animal models of MS and clinical trials in human patients. We also address the advantages of combining cell therapy with biomaterials.https://www.mdpi.com/2075-1729/12/4/474Multiple sclerosisremyelinationcell therapybiomaterials |
| spellingShingle | Eneritz López-Muguruza Natalia Villar-Gómez Jordi A. Matias-Guiu Belen Selma-Calvo Lidia Moreno-Jiménez Francisco Sancho-Bielsa Juan Lopez-Carbonero María Soledad Benito-Martín Silvia García-Flores Natalia Bonel-García Ola Mohamed-Fathy Kamal Denise Ojeda-Hernández Jorge Matías-Guiu Ulises Gómez-Pinedo The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination Life Multiple sclerosis remyelination cell therapy biomaterials |
| title | The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination |
| title_full | The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination |
| title_fullStr | The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination |
| title_full_unstemmed | The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination |
| title_short | The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination |
| title_sort | integration of cell therapy and biomaterials as treatment strategies for remyelination |
| topic | Multiple sclerosis remyelination cell therapy biomaterials |
| url | https://www.mdpi.com/2075-1729/12/4/474 |
| work_keys_str_mv | AT eneritzlopezmuguruza theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT nataliavillargomez theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT jordiamatiasguiu theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT belenselmacalvo theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT lidiamorenojimenez theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT franciscosanchobielsa theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT juanlopezcarbonero theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT mariasoledadbenitomartin theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT silviagarciaflores theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT nataliabonelgarcia theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT olamohamedfathykamal theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT deniseojedahernandez theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT jorgematiasguiu theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT ulisesgomezpinedo theintegrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT eneritzlopezmuguruza integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT nataliavillargomez integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT jordiamatiasguiu integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT belenselmacalvo integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT lidiamorenojimenez integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT franciscosanchobielsa integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT juanlopezcarbonero integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT mariasoledadbenitomartin integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT silviagarciaflores integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT nataliabonelgarcia integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT olamohamedfathykamal integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT deniseojedahernandez integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT jorgematiasguiu integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination AT ulisesgomezpinedo integrationofcelltherapyandbiomaterialsastreatmentstrategiesforremyelination |